Dietary Supplements and Inflammation Phase-2

膳食补充剂和炎症第二阶段

基本信息

批准号：
10227905
负责人：
Mitzi Nagarkatti
金额：
$ 197.23万
依托单位：
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-01 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10227905
关键词：
Acute Disease Advisory Committees Aging Alternative Medicine Area Attenuated Autoimmune Diseases Award Botanicals Brain Cardiovascular Diseases Cell physiology Cells Centers of Research Excellence Chronic Chronic Disease Clinical Communicable Diseases Complement Complementary Medicine Complementary and alternative medicine Core Facility Development Disease Distress Entrepreneurship Epigenetic Process Extramural Activities Faculty Financial Support Flow Cytometry Foreign Bodies Funding Ginseng Preparation Goals Grant Healthy People 2020 Heart Hispanic Americans Holistic Medicine Homeostasis Human Hypersensitivity Individual Indoles Inflammation Inflammatory Interdisciplinary Study International Invaded K-Series Research Career Programs Knowledge Laboratories Lead Legal patent Liver Malignant Neoplasms Mentors Mentorship Modality Neurodegenerative Disorders Obesity Organ Pathogenesis Phase Pilot Projects Play Population Preventive Quercetin Reducing Agents Reporting Research Research Infrastructure Research Personnel Research Project Grants Resveratrol Role Scientist Secure Services Small Business Innovation Research Grant Small Business Technology Transfer Research South Carolina Structure Testing Therapeutic Tissues Training Translational Research Trauma United States National Institutes of Health Universities analog autoimmune pathogenesis biomarker discovery career college dietary supplements effective therapy epigenetic regulation expectation experience immunoregulation innovation meetings member microscopic imaging multidisciplinary nervous system disorder novel novel therapeutics pathogen post-doctoral training pre-doctoral prevent programs recruit senior faculty success tenure track ward

项目摘要

Abstract: The overall objective of the COBRE Phase-2 for Dietary Supplements and Inflammation (CDSI) at the University of South Carolina (USC) is to continue to build on the success of Phase-1 and advance the research infrastructure specifically in the area of dietary supplements and inflammation by promoting multi-disciplinary research pursued by junior investigators so that they become highly competitive in obtaining NIH R01 grants and similar type of extramural funding to pursue their research. The overall objective is to investigate how botanicals can attenuate inflammation and be used to prevent and/or treat inflammatory diseases. The CDSI will test the overarching hypothesis that botanicals or their constituents regulate inflammation through epigenetic regulation of immune cell functions. In Phase-1, we have made outstanding progress in the successful transition of all of our junior faculty into extramurally-funded investigators. Additionally, we were successful in securing NIH Complementary and Alternative Medicine (CAM) Center (P01) for Epigenetic Regulation of Inflammation, in which ‘graduated’ faculty are leading the projects, thereby paving the path towards sustainability of CDSI. Thus, the CDSI will complement the CAM Research and create a unique niche at USC in inflammation research. The main goal of COBRE Phase-2 is to establish multi-disciplinary research that will identify the epigenetic mechanisms through which botanicals modulate inflammation so that they or their analogs can be used to prevent and/or treat inflammatory diseases. The US population spends ~$33.9 billion/year on CAM, of which ~$20 billion is on dietary supplements. It is becoming increasingly clear that inflammation plays a critical role in the pathogenesis of not only autoimmune diseases but also a wide range of clinical disorders including cardiovascular diseases, neurodegenerative disorders, obesity, aging and cancer. Thus, understanding the mode of action of botanicals or their constituents on inflammation, could lead to novel treatment modalities with far ranging clinical implications. The CDSI goal will be accomplished through promotion of multi-disciplinary research pursued by 4 junior faculty in the area of inflammatory diseases, through highly structured mentoring of each by a senior faculty and a recently graduated faculty member of the COBRE Phase-1. The junior faculty will have access to state-of-the-art research core facilities that include Flow Cytometry, Microscopy and Imaging Core, and Bioanalytical Core, to aid epigenetic studies. The program will be evaluated by an External Advisory Committees consisting of nationally recognized scientists. Additionally, through institutional support, 5 new tenure-track junior faculty will be recruited and mentored at USC to bolster and advance inflammation research. The long term objective of the CDSI would be to build a self-sustaining, nationally and internationally recognized multi-disciplinary Center for dietary supplements and inflammation research, by promoting innovation, faculty entrepreneurship, collaborative research projects such as PPGs and Institutional training grants, and clinical/translational research.

抽象的：大学膳食补充剂和炎症 (CDSI) 的 COBRE 第 2 阶段的总体目标南卡罗来纳州 (USC) 将继续在第一阶段成功的基础上推进研究通过促进多学科的合作，特别是在膳食补充剂和炎症领域建立基础设施初级研究人员进行的研究，使他们在获得 NIH R01 资助方面具有很强的竞争力，类似类型的外部资助来开展他们的研究，总体目标是研究植物药如何发挥作用。可以减轻炎症并用于预防和/或治疗炎症性疾病。植物药或其成分通过表观遗传调控调节炎症的总体假设在第一阶段，我们在所有免疫细胞功能的成功转变方面取得了显着进展。此外，我们还成功地确保了 NIH 的安全。炎症表观遗传调节补充和替代医学 (CAM) 中心 (P01)，位于这些“毕业”教师正在领导这些项目，从而为 CDSI 的可持续发展铺平了道路。 CDSI 将补充 CAM 研究，并在南加州大学炎症研究领域创造独特的利基市场。 COBRE 第 2 阶段的主要目标是建立多学科研究，以确定表观遗传植物药调节炎症的机制，因此它们或它们的类似物可用于预防和/或治疗炎症性疾病美国人口每年在 CAM 上花费约 339 亿美元，其中约 200 亿美元用于膳食补充剂，炎症在其中发挥着至关重要的作用，这一点变得越来越明显。不仅是自身免疫性疾病的发病机制，而且是多种临床疾病的发病机制，包括心血管疾病、神经退行性疾病、肥胖、衰老和癌症。植物或其成分对炎症的作用方式可能会导致新的治疗方式 CDSI 的目标将通过促进多学科来实现广泛的临床影响。 4 名初级教师通过高度结构化的指导在炎症性疾病领域开展研究每个项目均由 COBRE 第一阶段的高级教职人员和最近毕业的教职人员负责。将可以使用最先进的研究核心设施，包括流式细胞仪、显微镜和成像核心和生物分析核心，以帮助表观遗传学研究该计划将由外部顾问进行评估。此外，通过机构支持，由国家认可的科学家组成的委员会新增了 5 名。南加州大学将招募和指导终身教授的初级教师，以支持和推进炎症研究。 CDSI 的长期目标是建立一个自我维持、国内和国际认可的组织膳食补充剂和炎症研究的多学科中心，通过促进创新、教师创业、合作研究项目，例如 PPG 和机构培训补助金，以及临床/转化研究。